The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis.

Aim: To investigate the cost-effectiveness of blue-light therapy versus a two-compound formulation (TCF) (Dovobet gel [calcipotriol and betamethasone]) in mild-to-moderate psoriasis.

Methods: A Markov model was applied to describe the course of disease among Dutch patients with a Psoriasis Area and Severity Index (PASI) score ≤ 10 over a 52-week time horizon. Patients received either 12-week blue-light therapy or two 4-week treatments with TCF.